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MALAT1 is a long noncoding RNA known to be mis-
regulated in many human cancers. We have identi-
fied a highly conserved small RNA of 61 nucleotides
originating from the MALAT1 locus that is broadly
expressed in human tissues. Although the long
MALAT1 transcript localizes to nuclear speckles,
the small RNA is found exclusively in the cytoplasm.
RNase P cleaves the nascent MALAT1 transcript
downstream of a genomically encoded poly(A)-rich
tract to simultaneously generate the 30 end of the
mature MALAT1 transcript and the 50 end of the small
RNA. Enzymes involved in tRNA biogenesis then
further process the small RNA, consistent with its
adoption of a tRNA-like structure. Our findings reveal
a 30 end processing mechanism by which a single
gene locus can yield both a stable nuclear-retained
noncoding RNA with a short poly(A) tail-like moiety
and a small tRNA-like cytoplasmic RNA.
INTRODUCTION
Although it has been generally assumed that most genetic
information is expressed as and transacted by proteins, the
majority of the mammalian genome is transcribed, yielding
a complex network of overlapping transcripts that includes
tens of thousands of long noncoding RNAs (ncRNAs) with little
or no protein-coding capacity (Carninci et al., 2005; Birney
et al., 2007; Kapranov et al., 2007). Few long ncRNAs have
been assigned a function; however, a significant number of these
transcripts are unlikely to represent transcriptional ‘‘noise’’ as
they have been shown to exhibit cell type-specific expression,
localization to specific subcellular compartments, and associa-
tion with human diseases (reviewed in Prasanth and Spector,
2007; Szymanski et al., 2005; Costa, 2005; Mercer et al., 2008).
Among those shown to be functional, Xist ncRNA is involved in
mammalian X inactivation (Masui and Heard, 2006), the roX
genes mediate X chromosome hyperactivation in Drosophila
(reviewed in Deng and Meller, 2006), and several long ncRNAs,including Air, have been implicated in genomic imprinting
(Braidotti et al., 2004).
A recent study suggested that the function of a significant frac-
tion (40%) of long unannotated transcripts may be to serve as
precursors for small RNAs less than 200 nt in length (Kapranov
et al., 2007). Consistent with this hypothesis, the H19 imprinted
gene was originally suggested to function as an 2.3 kb ncRNA
but has recently been shown to serve as a microRNA precursor
(Cai and Cullen, 2007). In addition to microRNAs that regulate
RNA degradation and translation (Filipowicz et al., 2008; Vasu-
devan et al., 2007) and piRNAs that silence transposons in the
germline (Brennecke et al., 2007; Carmell et al., 2007), other
classes of small RNAs have been recently discovered. These
include small RNAs that are present near the 50 and 30 ends of
genes (PASRs and TASRs, respectively), although the mecha-
nisms of their biogenesis and their functions remain to be deter-
mined (Kapranov et al., 2007).
MALAT1 (metastasis-associated lung adenocarcinoma tran-
script 1) was originally identified in a screen for transcripts whose
expression was altered in early-stage non-small cell lung
cancers that had a propensity for metastasis (Ji et al., 2003). Ex-
pression of the previously uncharacterized RNAwas increased in
tumors that later metastasized compared to those that did not,
indicating the prognostic value of MALAT1 for metastasis. Addi-
tionally, high expression of MALAT1 was found to be associated
with significantly decreased patient survival. Curiously, MALAT1
lacks open reading frames of significant length, and in vitro
translation of MALAT1 yielded no peptides, suggesting that
MALAT1 functions as a long (7 kb) noncoding RNA (Ji et al.,
2003; Lin et al., 2006).
MALAT1 shows broad expression in normal human and
mouse tissues (Ji et al., 2003; Hutchinson et al., 2007) and is
overexpressed in many human carcinomas, including those of
the breast, pancreas, lung, colon, prostate, and liver (Lin et al.,
2006), implying that MALAT1 misregulation may play a role in
the development of numerous cancers. Chromosomal translo-
cation breakpoints associated with cancer have also been
identified within the MALAT1 locus (Davis et al., 2003; Kuiper
et al., 2003; Rajaram et al., 2007). Recently, it has been shown
that MALAT1 is specifically retained in the nucleus in nuclear
speckles (Hutchinson et al., 2007), domains that are thought to
be involved in the assembly, modification and/or storage of the
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Spector, 2003). Such localization is indicative of MALAT1
playing a potential role in the organization or regulation of gene
expression.
In the present study, we investigated whether MALAT1 may
also function as a precursor for the production of small RNAs.
We have identified a highly conserved, tRNA-like noncoding
RNA that maps near the 30 end of the MALAT1 locus. Northern
blot analysis showed that the 61 nt RNA is broadly expressed
in normal human tissues. In contrast to the stable nuclear-
retained MALAT1 transcript, the 61 nt RNA is exclusively local-
ized to the cytoplasm and has a relatively short half-life (and
thus we have named it mascRNA, MALAT1-associated small
cytoplasmic RNA). We show that 30 end processing of MALAT1
yields the mascRNA transcript. RNase P cleaves downstream
of a genomically encoded poly(A)-rich tract to simultaneously
generate the 30 end of MALAT1 and the 50 end of mascRNA.
This 30 end processing mechanism results in the presence of
a short poly(A) tail-like moiety on the 30 end of MALAT1. These
results reveal a 30 end processing mechanism by which a single
gene locus can yield both a stable nuclear-retained ncRNA and
a small tRNA-like cytoplasmic RNA.
RESULTS
Identification of a Highly Conserved Small Noncoding
RNA Originating from the MALAT1 Locus
MALAT1 is a long noncoding transcript that specifically localizes
to nuclear speckles, shows broad expression in mouse and
human normal tissues, and is overexpressed in numerous can-
cers (Hutchinson et al., 2007; Lin et al., 2006; Ji et al., 2003).
Within theMALAT1 transcript, there are short blocks of high con-
servation, especially in the 30 half of the RNA, that may represent
functional elements such as binding sites for proteins, nuclear
localization signals, or sequences for the generation of small
RNAs (Figure 1A). To determine whether any small RNAs map
to the mouse MALAT1 (mMALAT1) gene locus, we isolated an
enriched fraction of small RNAs under 200 nucleotides from
mouse EpH4 mammary epithelial cells. These cells had been
stably transfected with an empty vector (EpH4-EV cells) or a vec-
tor that overexpresses the ErbB2 oncogene (EpH4-A6 cells) to
induce cellular transformation (Fantin et al., 2002). Normal and
transformed EpH4 cells were used because expression of
mMALAT1 increases 2.5-fold in response to ErbB2 overexpres-
sion (Figure S1 available online) and overexpression of MALAT1
has been previously linked to various cancers.
Small RNA northern blots were then performed with four
different probes, each approximately 1.6 kb in length, to span
the7 kb sequence of mMALAT1 (Figure 1B). Probes to themid-
dle of mMALAT1 did not hybridize to any small RNA, whereas
a probe to nt 71 to 1687 hybridized to three RNA species of
approximately 90, 150, and over 200 nt in length, and a probe
to nt 5183 to 6843 of mMALAT1 hybridized to a single RNA
species of 61 nt in length (note that all mMALAT1 nucleotide
numbering is based on GenBank accession number AY722410).
Upon further mapping the small RNAs hybridizing to the 50 end
of mMALAT1, it was determined that all three RNAs map to the
SINE element and thus probably do not originate frommMALAT1
(Figure S2).920 Cell 135, 919–932, November 28, 2008 ª2008 Elsevier Inc.To further map the small RNA originating from the 30 end of
mMALAT1, we divided the original 1.6 kb probe into several
shorter probes that were used to show that the 61 nt RNA
originated from within nt 6703 to 6843 (Figures S3A and S3B).
Oligonucleotide probes were then used to show that a probe
complementary to nt 6703 to 6752 of mMALAT1 specifically
hybridizes to the 61 nt RNA, indicating that the small RNA
originates from the same strand asmMALAT1 (Figure 1C). An an-
tisense probe to nt 6653 to 6702 of mMALAT1 was also able to
weakly detect the small RNA, suggesting that the small RNA
spanned the two probes (data not shown). By performing north-
ern blots with multiple 20 nt oligonucleotide probes that tiled this
region, we concluded that the small RNAmaps to approximately
nt 6690 to 6750 of mMALAT1 (Figure S3C). In contrast to
mMALAT1, small RNA expression did not significantly change
upon transformation of EpH4 cells. When we examined small
RNA transcriptomemaps thatwere generatedwith genomic tiling
arrays (Kapranov et al., 2007), we noted that the 61 nt RNA was
not detected by thismethodology, possibly because of RNA sec-
ondary structure or the threshold employed (data not shown).
We have named this 61 nt RNA mascRNA (MALAT1-associ-
ated small cytoplasmic RNA) for the reasons stated below. The
mascRNA transcript is highly conserved and present in multiple
species, including mouse, human, dog, lizard, X. tropicalis, and
stickleback (Figure 1D). There are only four mismatches between
the mouse and human orthologs. Interestingly, mascRNA is at
the 30 end of an 160 nt region that is highly conserved among
these species, suggesting that the upstream region may be im-
portant for the biogenesis of themascRNA transcript (Figure S4).
Immediately upstream of mascRNA is a conserved poly(A)-rich
tract (16/18 adenines in mouse, 17/19 adenines in human). Fur-
ther upstream, there are two nearly perfectly conserved 10 nt
U-rich motifs separated by a conserved predicted stem loop.
No translation initiation codons or stop codons are present
within the mascRNA transcript (Figure 1E), indicating that it likely
functions as a small noncoding RNA.
ThemascRNATranscript Is Broadly Expressed inHuman
Tissues
Because the mascRNA transcript is highly conserved, we exam-
ined whether the 61 nt RNA is also expressed in human cell lines
and tissues. Using an antisense probe to the syntenic region of
human MALAT1 (hMALAT1), we were able to detect expression
of the 61 nt human mascRNA ortholog in multiple cell lines, in-
cluding HeLa (Figure 2A) and MCF10A (data not shown) (note
that all hMALAT1 nucleotide numbering is based on GenBank
accession number BK001418). Next, we examined the expres-
sion of the human mascRNA transcript in 20 normal human
tissues and found that the small RNA is broadly expressed
(Figure 2B), which is not surprising, given that the long MALAT1
transcript is also broadly expressed (Ji et al., 2003; Hutchinson
et al., 2007).
To further verify that the 61 nt RNA we detected on the north-
ern blots originates from the MALAT1 locus, we took advantage
of several point mutations between the mouse and human
mascRNA sequences. On the basis of these differences, we
designed a 25 nt probe complementary to nt 6728 to 6752 of
mMALAT1 that should be able to distinguish between the mouse
Figure 1. A 61 nt Small RNA Maps Near the 30 End of mMALAT1
(A) The MALAT1 locus, located on mouse chromosome 19, has been reported to yield an 7 kb noncoding transcript (transcription start site denoted by arrow)
that contains regions of high conservation. MALAT1 lacks repetitive elements except for a SINE and LINE element near its 50 end.
(B) Small RNAs were isolated from EpH4-EV (denoted EV) and EpH4-A6 (denoted A6) cells. Four different probes that span the mMALAT1 locus were used for
northern blot analysis as designated at the bottom of each blot. U6 snRNA was used as a loading control.
(C) Strand-specific oligonucleotide probes were used to further map the 61 nt small RNA. Sense probes detect transcripts originating from the opposite strand of
mMALAT1, whereas antisense probes detect transcripts originating from the same strand as mMALAT1.
(D) The 61 nt mascRNA transcript is highly conserved (sequence shown as DNA and does not include CCA at the 30 end, which is added during processing).
(E) The mascRNA transcript lacks translation initiation and stop codons.Cell 135, 919–932, November 28, 2008 ª2008 Elsevier Inc. 921
Figure 2. mascRNA Is Broadly Expressed in Normal Human Tissues
(A) Northern blot analysis using strand-specific oligonucleotide probes showed that the human mascRNA ortholog is expressed in HeLa cells. U6 snRNA was
used as a loading control.
(B) Ten micrograms of total RNA from 20 normal human tissues was probed for mascRNA expression.
(C) A 25 nt probe complementary to nt 6728–6752 of mMALAT1 was designed. The 25 nt probe specifically distinguished expression of the mouse isoform in
EpH4-EV cells from the human isoform in HeLa cells.and human mascRNA orthologs when hybridized at 42 degrees
by only detecting mouse mascRNA (Figure 2C). As shown, the
25 nt probe only detected the mouse isoform, confirming that
the small RNA detected on the northern blots originates from
the MALAT1 locus.
mascRNA Is a tRNA-like RNA Polymerase II Transcript
that Localizes to the Cytoplasm
Upon treating total RNA with a 50 phosphate-dependent exonu-
clease, we found that mascRNA is not susceptible to degrada-
tion, suggesting that it lacks a 50 monophosphate (Figure 3A,
lanes 1 and 2). However, this exonuclease fails to digest dou-
ble-stranded RNA or RNA with extensive secondary structure
such as tRNAs. We thus reasoned that the mascRNA secondary
structure may make the transcript insensitive to digestion and922 Cell 135, 919–932, November 28, 2008 ª2008 Elsevier Inc.that mascRNA may actually have a 50 monophosphate. To dis-
rupt the mascRNA secondary structure, we hybridized total
RNA to DNA oligonucleotides complementary to mascRNA
and then subjected them to digestion by RNase H (Figure 3A,
lanes 3–6). The 50 phosphate-dependent exonuclease was able
to digest the shorter mascRNA 50 fragments, indicating that there
is a 50 monophosphate on mascRNA. Using a ligation-based
small RNA cloning procedure, we then defined the 50 end of
mascRNA to be at exactly nt 6691 of mMALAT1 (which is equiv-
alent to nt 7519 of hMALAT1) (Figure S5).
We similarly cloned the 30 end of mascRNA using a ligation-
based approach and found that mascRNA has a 30 hydroxyl
group (Figure 3C). To our surprise, all sequenced mouse
(Figure 3C) and human (data not shown) mascRNA cDNA clones
ended in 30-terminal CCA, which is not encoded in the genome
and is a hallmark of the 30 ends of tRNAs and tRNA-like struc-
tures (reviewed in Hopper and Phizicky, 2003). Upon folding
the 61 nt mascRNA transcript using Mfold, we found that
mascRNA is predicted to fold similar to a tRNA cloverleaf
secondary structure (Zuker, 2003; Mathews et al., 1999)
(Figure 3B). This tRNA-like structure of mascRNA has been pre-
served through evolution, as the four mismatches between the
mouse and human orthologs maintain the cloverleaf secondary
structure. Although similar in structure to a tRNA and containing
a well-conserved B box (Figure S4), the 61 nt mascRNA
transcript is smaller than most tRNAs (76 nt) and has a small,
relatively poorly conserved anticodon loop. This suggests that
mascRNA does not function in transferring a specific amino
acid to a growing polypeptide chain during protein synthesis.
By performing polyacrylamide gel electrophoresis under
acidic conditions to look at aminoacylation levels of tRNAs
in vivo (Varshney et al., 1991), we found no evidence that
Figure 3. mascRNA Is an RNAPolymerase II
tRNA-like Transcript that Localizes to the
Cytoplasm
(A) A 50-phosphate-dependent exonuclease was
used to show that mascRNA has a 50-monophos-
phate group. In lanes 3–6, EpH4-A6 total RNA was
first treated with antisense oligonucleotides (as
designated at top) complementary to mascRNA
and subjected to RNase H treatment. A probe
complementary to nt 6690–6709 of mMALAT1
was used for the northern blot. The microRNA
let-7a was used as a positive control for exonucle-
ase activity, whereas U4 snRNA is capped and
serves as a loading control.
(B) The mature mouse mascRNA transcript is
predicted to form a tRNA-like cloverleaf second-
ary structure. The four point mutations between
the mouse and human orthologs are shaded.
The * designates the nucleotide that is commonly
modified.
(C) The 30 end of mouse mascRNA was cloned
with a ligation-based approach (30 linker oligo is
designated). All sequenced mascRNA cDNA
clones end in CCA, and six of eight clones show
a common nucleotide modification.
(D) Total RNA from HeLa cells treated with
50 mg/mL of a-amanitin, an RNA polymerase II
inhibitor, for 6 or 12 hr was subjected to northern
blot analysis.
(E) EpH4-EV and EpH4-A6 cells were fractionated
to isolate nuclear and cytoplasmic total RNA,
which was then subjected to northern blot analysis
with a probe to nt 6563–6843 of mMALAT1. The
longmMALAT1 transcript was exclusively nuclear,
whereas the mascRNA transcript was exclusively
cytoplasmic.
mascRNA is aminoacylated in HeLa
cells (Figure S6). mascRNA cloning also
revealed that at least one nucleotide of
mascRNA is commonly modified be-
cause the genomic A at mMALAT1 nt
6733was sequenced as a G in six of eight
mouse clones (Figure 3C), suggestive of posttranscriptional
modification of adenine to inosine (A-to-I editing) (reviewed in
Bass, 2002).
MALAT1 is known to localize to nuclear speckles (Hutchinson
et al., 2007), and thus wewere interested in determining to which
subcellular compartment the 61 nt mascRNA transcript local-
izes. Using biochemical fractionation to separate nuclear and
cytoplasmic total RNA from EpH4-EV and EpH4-A6 cells, we
were able to confirm that the long mMALAT1 transcript is exclu-
sively nuclear (Figure 3E). In contrast, mascRNA is exclusively
cytoplasmic in EpH4 (Figure 3E) andHeLa cells (data not shown).
To examine whether mascRNA is associated with polysomes,
we harvested exponentially growing HeLa cells and prepared
and displayed cytoplasmic extracts on sucrose gradients
(Figure S8). Unlike microRNAs, mascRNA does not associate
with polysomes but instead associates with lighter fractions
where tRNAs are present. In summary, two noncodingCell 135, 919–932, November 28, 2008 ª2008 Elsevier Inc. 923
transcripts are produced from the MALAT1 gene locus; interest-
ingly, each localizes to a different subcellular compartment,
implying that they may have distinct functions.
We were next interested in determining whether mascRNA is
made via processing of MALAT1 or whether the small RNA is
derived from a separate, overlapping transcriptional unit. First,
we addressed whether mascRNA is an RNA polymerase II
transcript by incubating HeLa cells with a-amanitin, an RNA poly-
merase II inhibitor (irreversible in tissue culture cells at 50 mg/ml).
mascRNA expression decreased greater than 70% after 6 hr of
a-amanitin treatment and was undetectable after 12 hr, consis-
tent with the small RNA being an RNA polymerase II transcript
with a relatively short half-life (Figure 3D, top panel; Figure S7A).
Interestingly, MALAT1 was present at significant levels in HeLa
cells even after prolonged transcriptional inhibition, indicating
low turnover and an RNA half-life of greater than 12 hr (Figure 3D,
bottom panel). As further support that mascRNA is an RNA poly-
merase II transcript, mascRNA expression rapidly decreased
when HeLa cells were incubated with a lower concentration of
a-amanitin (Figure S7B) or with DRB (5,6-dichloro-1-b-D-
ribofuranosylbenzimidazole), another RNA polymerase II inhibitor
(Figure S7C). These results are consistent with a model in which
mascRNA is derived from an RNA polymerase II transcript but
do not definitively prove that MALAT1 is the precursor.
The Abundant MALAT1 Transcript Ends Immediately
Upstream of mascRNA
Mouse MALAT1 has been reported to be an abundant 7 kb
polyadenylated RNA (Lin et al., 2006; Hutchinson et al., 2007).
However, the exact size of long transcripts can be difficult to pre-
cisely determine via northern blot analysis. Therefore, we used
multiple oligonucleotide probes to map what regions are and
are not part of the abundant mMALAT1 transcript (Figure 4A).
Consistent with previous reports, multiple oligo probes comple-
mentary tomMALAT1were able to detect a single long transcript
(Figure 4B, probes A andB). Unexpectedly, a probe complemen-
tary to the mascRNA region was unable to detect the long
mMALAT1 transcript (Figure 4B, probe D), indicating that this
region may be spliced out of mMALAT1 or that the 30 end of
mMALAT1 is further upstream than has been reported. We
were unable to detect any mMALAT1 transcripts that were
spliced in this region by RT-PCR (data not shown), suggesting
that RNA splicing can not explain our observation.
To roughly determine the location of the 30 end of mMALAT1,
we used multiple probes complementary to the region the
mascRNA transcript originates from and flanking sequences
(Figure 4A, probes C–H). Using an antisense probe to the region
immediately upstream of mascRNA, we were able to detect the
long mMALAT1 transcript (Figure 4C, probe C). In contrast, an
antisense probe to the mascRNA region or any other probe after
nt 6700 was unable to detect mMALAT1 (Figure 4C, probes
D–H). These northern blots thus show that the abundant
mMALAT1 transcript is only 6.7 kb in length and ends immedi-
ately upstream of the mascRNA transcript. 30 RACE PCR
showed that the previously reported 7 kb polyadenylated
mMALAT1 transcript is present in cells (data not shown), but it
is at a low level that is not detectable by northern blot analysis
with 10 mg of total RNA. Therefore, we conclude that mMALAT1924 Cell 135, 919–932, November 28, 2008 ª2008 Elsevier Inc.can generate two long transcripts (6.7 kb and 7 kb in mouse)
that differ in the location of their 30 ends. Using 50 RACE PCR, we
were only able to detect mMALAT1 transcripts starting at the
previously identified start site (Hutchinson et al., 2007), suggest-
ing that there are no other mMALAT1 promoters (data not
shown).
Human MALAT1 has been reported to be an8.7 kb polyade-
nylated transcript that utilizes a promoter 1.3 kb upstream of
the promoter that the mouse ortholog utilizes (Hutchinson
et al., 2007) (Figure S9A). We determined that the hMALAT1 tran-
script observed on a northern blot utilizes the same promoter as
the mouse ortholog and is only 7 kb in length (Figure S9B). We
then addressed whether the abundant hMALAT1 transcript
ends immediately upstream of the mascRNA region similar to
mMALAT1. Indeed, any probe complementary to regions 50 of
the small RNA was able to detect the long hMALAT1 transcript,
whereas probes to the mascRNA region or sequences further
downstream were unable to detect the long transcript by north-
ern blot analysis (Figure S10).
The Abundant MALAT1 Transcript Has a Short Poly(A)
Tail-like Moiety
There are no canonical cleavage/polyadenylation signals lo-
cated in the immediate vicinity of where the abundant MALAT1
transcript ends (Figure 4D and Figure S4). Instead, we identified
a conserved poly(A)-rich tract (16/18 adenines in mouse, 17/19
in human) encoded in the genome immediately upstream of the
mascRNA transcript (Figure 4D). To better define the location of
the 30 end of the abundant MALAT1 transcript and determine
whether it has a canonical poly(A) tail, we carried out RNase H
digestion followed by northern analysis. Total RNA from HeLa
cells was hybridized to specific DNA oligos, subjected to
digestion by RNase H, and run on a small RNA northern blot
to allow high-resolution mapping of the 30 end of the hMALAT1
transcript (Figure 4E). In contrast to a normal polyadenylated
RNA, which would give a smear because of variable poly(A)
tail lengths, the abundant hMALAT1 transcript yielded
defined bands. These results indicated that MALAT1 30 end
cleavage occurs at a defined position and that there is not
subsequent addition of nucleotides as occurs during polyade-
nylation.
To further confirm the RNase H-based mapping studies, we
performed a modified form of 30 RACE PCR in which an RNA
adaptor was ligated to the 30 ends of HeLa and EpH4-EV total
RNA followed by reverse transcription using a primer comple-
mentary to the adaptor. Upon sequencing multiple clones, we
determined that the RNA adaptor is able to be ligated to the 30
end of the abundant MALAT1 transcript, confirming that there
is a 30 hydroxyl group, and that 30 end cleavage occurs exactly
after nt 7518 of hMALAT1 (nt 6690 of mMALAT1) (Figure 4D
and Figure S11). The 30 cleavage site is immediately after the
genomically encoded poly(A)-rich tract, indicating that 30 end
processing of the abundant MALAT1 transcript results in a short
poly(A) tail-like moiety. When poly(A)+ RNA from mouse EpH4-
EV cells was isolated, the abundant 6.7 kb mMALAT1
transcript is indeed present in the poly(A)+ fraction (Figure 4F).
No signal was detected when a probe (6703–6752 antisense)
that can detect only the 7 kb transcript was used, indicating
Figure 4. The Abundant MALAT1 Transcript Ends Immediately Upstream of mascRNA
(A) Antisense probes complementary to mMALAT1 were designed and used in (B) and (C).
(B) Ten micrograms of total RNA from EpH4-A6 cells was probed by northern blot analysis with the designated oligonucleotide probes. b-actin was used as a
loading control.
(C) Northern blots revealed that the 30 end of the abundant mMALAT1 transcript is further upstream than previously reported, and, therefore, the abundant
transcript is only 6.7 kb in length.
(D) A conserved poly(A)-rich tract is present immediately upstream of mascRNA. Numbers at the top denote the mouse nucleotide position, whereas numbers at
the bottom denote the corresponding human nucleotide position.
(E) RNase H digestion and then northern blot analysis was used to map the 30 end of the abundant human MALAT1 transcript in HeLa cells. ASO1 is
complementary to nt 7381–7430 of hMALAT1. ASO2 is complementary to nt 7331–7380 of hMALAT1. Both antisense oligonucleotides result in RNase H cleavage
products that suggest that the 30 end of the long hMALAT1 transcript is at nt 7520.
(F) Total and poly(A)+ RNA were isolated from EpH4-EV cells and probed by northern blot analysis to show that the6.7 kb mMALAT1 transcript is present in the
poly(A)+ fraction.that the observed poly(A)+ signal with the 6653–6702 antisense
probe is not due to the low level of the 7 kb polyadenylated
mMALAT1 transcript present in cells.Despite having a short poly(A) tail-likemoiety,MALAT1 is a sta-
ble noncoding RNA (Figure 3D, bottom panel). It has previously
been shown that the poly(A) tail of a viral nuclear-retained RNACell 135, 919–932, November 28, 2008 ª2008 Elsevier Inc. 925
Figure 5. Antisense Oligonucleotides Inhibit mMALAT1 Upstream 30 End Processing, Resulting in a Decrease in mascRNA Expression
(A) Antisense oligonucleotides (ASOs) complementary to the mascRNA transcript and flanking regions were designed. Numbers to the left of each ASO represent
lane number in (B). Probe A recognizes both the 6.7 kb and 7 kb mMALAT1 isoforms, whereas probe B only recognizes the 7 kb mMALAT1 isoform.
(B) Northern blots were performed to determine the effect of ASO treatment on expression of the7 kbmMALAT1,6.7 kbmMALAT1, andmascRNA transcripts.
The data in the bar graphs are shown as mean and standard deviation values of three independent transfections. Representative northern blots are shown.interacts with an upstreamU-rich element to stabilize the RNAby
inhibiting deadenylation (Conrad et al., 2006). We reasoned that
the conserved U-rich motifs present upstream of mascRNA
(Figure S4) may play a similar role in stabilizing the poly(A)
tail-like moiety of MALAT1. Indeed, upon mutation of one of
the U-rich motifs, MALAT1 was rapidly deadenylated in vitro
when incubated with HeLa extracts under decay conditions
(Ford et al., 1999), implicating the U-rich motifs in stabilizing
the abundant MALAT1 transcript (Figure S12).
30 End Processing of MALAT1 in the Nucleus
Yields the mascRNA Transcript
Although the mapping of the 30 end of MALAT1 and the 50 end of
mascRNA to the same nucleotide position (Figure 4D) suggests
thatmascRNAmay be generated via a formof a 30 end processing
reaction, it does not formally prove the precursor-product
relationship between the MALAT1 primary transcript and
mascRNA. For example, it is possible that although not detectable
in our analysis, mascRNA may use a different RNA polymerase II926 Cell 135, 919–932, November 28, 2008 ª2008 Elsevier Inc.promoter than that of the 6.7 kb mMALAT1 transcript. To
address this issue, we reasoned that transfection of antisense
oligonucleotides (ASOs) complementary to mascRNA and/or
flanking sequences may inhibit the RNA processing reaction by
altering the local RNA secondary structure or by sterically block-
ing the binding of proteins involved in the cleavage reaction. If
mascRNA is indeed a product of 30 end processing of the 6.7
kb mMALAT1 transcript, active ASOs must cause both (1) an in-
crease in the expression of the 7 kb polyadenylated mMALAT1
transcript (because cleavage upstreamat6.7 kbwill be blocked)
and (2) a corresponding decrease in mascRNA expression.
We designed ten 20-mer antisense oligonucleotides with a
20-O-methoxy-ethyl ribose (MOE) phosphorothioate backbone
that are complementary to mMALAT1, as well as an unrelated
oligonucleotide that was used as a negative control (Figure 5A).
This backbone modification imparts a very high affinity for
targeted RNA and resistance to both exo- and endonucleases,
and it does not support cleavage of hybridized RNA by RNase
H (Monia et al., 1993; McKay et al., 1999). The ASOs were
transfected into EpH4-EV cells, and total RNA was isolated 24 hr
after transfection. To first determine whether any ASOs caused
an increase in the expression of the 7 kb mMALAT1 transcript,
we used a probe that can only detect the 7 kb transcript
(Figure 5A, probe B). Little to no 7 kb transcript was observed
in EpH4-EV cells that were mock transfected or treated with the
control oligonucleotide (Figure 5B, lanes 1 and 2), consistent
with our previous observation that the abundant mMALAT1
transcript is only 6.7 kb in length.
Numerous ASOs complementary to mMALAT1 caused an
accumulation of the 7 kb transcript, indicating that they were
active in inhibiting 30 end processing upstream at 6.7 kb
(Figure 5B). Two ASOs consistently caused expression of the
7 kb transcript to increase greater than 7-fold over Mock
(Figure 5B, lanes 6 and 10). Perhaps not surprisingly, one of
these most active ASOs (6640–6659, lane 10) is complementary
to the 30 end of the mascRNA transcript and thus directly inter-
fered with one of the cleavage sites (Figure 5A). The ASO com-
plementary to the mascRNA 50 cleavage site (6680–6699, lane
4) was also weakly active, but this ASO is complementary to
the poly(A)-rich tract, which has low sequence complexity and
thus reduced efficacy. The other most active ASO (6703–6722,
lane 6) targets within mascRNA and thus probably disrupts its
secondary structure. We verified that the observed band on
the northern blots was the 7 kb mMALAT1 polyadenylated
transcript by using additional probes complementary to the
regions upstream and downstreamof the cleavage/polyadenyla-
tion site at nt 6982 (Figure S13). After stripping the blot and using
a probe that can detect both the 6.7 and 7 kb transcripts
(Figure 5A, probe A), we observed a doublet (Figure 5B, lanes
4–6 and 10), showing that the ASOs do not affect the total
amount of mMALAT1 but do change the ratio between the
6.7 and 7 kb isoforms.
Next, we tested whether the ASOs caused a corresponding
decrease in mascRNA expression. Indeed, the two ASOs that
were most active in causing an accumulation of the 7 kb
mMALAT1 transcript also caused the largest decreases (50%–
60% knockdown) in mascRNA expression (Figure 5B, lanes 6
and 10). Interestingly, one ASO (6819–6838, lane 12) that was
targeted greater than 60 nt downstream of the mascRNA region
consistently caused an increase in mascRNA expression
(Figure 5B). We propose that this ASO inhibited cleavage/polya-
denylation downstream, resulting in a signal that caused
upstream 30 end processing to occur more often. The region
this ASO targetsmay play a role in regulating the choice between
downstream polyadenylation and upstream 30 cleavage. In
summary, we were able to identify several ASOs that caused
an accumulation of the 7 kb mMALAT1 transcript and a corre-
sponding decrease in mascRNA expression, supporting a
precursor-product relationship in which mascRNA is generated
from 30 end processing of the 6.7 kb mMALAT1 transcript.
Because the6.7 kb mMALAT1 transcript localizes to nuclear
speckles yet mascRNA localizes to the cytoplasm, two models
are possible for where the 30 end processing event occurs in
the cell. First, processing could occur in the nucleus (either
cotranscriptionally or posttranscriptionally at nuclear speckles)
with the mascRNA transcript subsequently being exported to
the cytoplasm. Alternatively, MALAT1 could be transcribed inthe nucleus as an7 kb polyadenylated transcript and exported
to the cytoplasm where it is further processed to yield the small
RNA. After processing, the6.7 kb MALAT1 transcript would be
imported back into the nucleus, whereas mascRNA remained in
the cytoplasm. To distinguish between these two possibilities,
we transfected the control ASO or the ASO complementary to
nt 6740–6759 into EpH4-EV cells. Twenty-four hours after trans-
fection, we fractionated cells to determine where the 7 kb
mMALAT1 transcript localized. If the processing reaction occurs
in the nucleus, we expected the 7 kb transcript to be in the nu-
clear fraction. In contrast, if the processing reaction occurs in the
cytoplasm, we expected the 7 kb transcript to accumulate in
the cytoplasmic fraction upon transfection of the ASO comple-
mentary to nt 6740–6759. As shown in Figure 6A, the 7 kb
mMALAT1 transcript localizes specifically to the nucleus, sug-
gesting that the processing reaction occurs in the nucleus,
followed by small RNA export to the cytoplasm. The ASOs had
no effect on the localization of mascRNA, which remained
exclusively cytoplasmic (Figure 6A).
MALAT1 Is a Substrate for RNase P and RNase Z
Because the processing event occurs in the nucleus and
mascRNA resembles a tRNA, we reasoned that RNase P, which
generates the 50 termini of mature tRNAs and is known to be nu-
clear (Jacobson et al., 1997; Gopalan et al., 2002), may catalyze
the endonucleolytic cleavage event that forms the 50 end of
mascRNA and the 30 end of the abundant MALAT1 transcript.
An 170 nt region of mMALAT1 that includes mascRNA at the
30 end (with or without CCA added) was cloned, transcribed
in vitro, and employed for RNase P in vitro cleavage assays. The
catalytic RNA component of E. coli RNase P (M1 RNA) was able
to cleave mMALAT1 in vitro, but only when CCA was already
present on the 30 end (Figure 6B). Partially purified human RNase
P from HeLa cells was also able to cleave mMALAT1 in vitro,
regardless of whether CCA was already present on the 30 end
(Figure 6C, left panel). Through the use of ligation-based small
RNA cloning procedures, the in vitro RNase P cleavage site
was mapped to the 50 end of mascRNA, confirming that both
in vitro systems accurately recapitulate in vivoMALAT1 process-
ing (data not shown).
RNase Z is an endoribonuclease that generates the 30 ends of
eukaryotic tRNAs prior to addition of the CCA motif (reviewed in
Vogel et al., 2005). Recombinant human RNase Z was able to
accurately cleave mMALAT1 in vitro to generate the 30 end of
mascRNA (Figure 6D). To then determine whether RNase P or
RNase Z cleavage occurs first, we used a mMALAT1 RNA
substrate that includes both 50 leader and 30 trailer sequences
for in vitro analysis. Human RNase P was able to accurately
cleave the mMALAT1 6581–6822 substrate at the 50 end of
mascRNA, indicating that RNase P cleavage can precede RNase
Z cleavage (Figure 6C, right panel). In contrast, RNase Z failed to
accurately cut the mMALAT1 6581–6822 substrate at the 30 end
of mascRNA in vitro (data not shown), consistent with previous
reports that RNase Z activity is inhibited by long 50 extensions
(de la Sierra-Gallay et al., 2005). We thus conclude that RNase
P first cleaves to simultaneously generate the 30 end of MALAT1
and the 50 end of mascRNA, followed by RNase Z cleavage toCell 135, 919–932, November 28, 2008 ª2008 Elsevier Inc. 927
generate the 30 end of mascRNA and then CCA addition to the 30
end of mascRNA (Figure 7).
DISCUSSION
MALAT1 has been suggested to function as a long noncoding
RNA that localizes to nuclear speckles and is misregulated in
numerous cancers (Ji et al., 2003; Lin et al., 2006; Hutchinson
et al., 2007). In the present study, we demonstrated that the
nascent MALAT1 transcript is processed to yield two noncoding
RNAs via an unanticipated 30 end processing mechanism. A
highly conserved tRNA-like structure present near the 30 end of
the MALAT1 nascent transcript is recognized and cleaved by the
tRNA processing machinery to yield a 61 nt small RNA. Unlike
the stable nuclear-retained long MALAT1 transcript, the 61 nt
mascRNA transcript localizes to the cytoplasm and has a rela-
tively short half-life.
A Single Gene Locus Yields Both a Stable Nuclear
Retained ncRNA and a Small tRNA-like Cytoplasmic RNA
Long RNA polymerase II transcripts have been previously shown
to be precursors for multiple types of small RNAs, including
snoRNAs (Kiss et al., 2006), microRNAs (Lee et al., 2004; Cai
et al., 2004), and possibly piRNAs (Brennecke et al., 2007; Guna-
wardane et al., 2007). Here, we have shown that RNA polymer-
ase II transcripts can also be precursors for tRNA-like small
RNAs. Via a single cleavage event by RNase P, the 30 end of
Figure 6. RNase P and RNase Z Cleave
MALAT1 in the Nucleus to Yield the
mascRNA Transcript
(A) After ASO transfection, EpH4-EV cells were
fractionated to isolate nuclear and cytoplasmic
total RNA. The 7 kb mMALAT1 transcript was
nuclear retained, and ASO treatment did not affect
the cytoplasmic localization of mascRNA. U6 and
let-7a were used as controls for fractionation
efficiency.
(B) MALAT1 can be cleaved in vitro by E. coli
RNase P. M1 RNA from E. coli was incubated for
1 hr at 37C with uniformly labeled MALAT1 sub-
strates. Samples were then electrophoresed in
an 8% polyacrylamide gel containing 8 M urea.
(C) MALAT1 can be cleaved in vitro by partially
purified human RNase P.
(D) Recombinant His-tagged human RNase Z
cleavesMALAT1 in vitro at the 30 end of mascRNA.
the abundant MALAT1 transcript and the
50 end of the mascRNA transcript are si-
multaneously generated (Figure 7). Inter-
estingly, mascRNA is at the 30 terminus
of MALAT1, and tRNA-like structures at
the 30 ends of RNAs have been proposed
to have served as genomic tags in the
RNA world (Weiner and Maizels, 1987).
After processing, the long MALAT1 tran-
script remains in the nucleus, whereas
mascRNA is exported to the cytoplasm.
This regulatory mechanism thus allows a single gene locus to
produce two noncoding RNAs that localize to different sub-
cellular compartments and have separate (possibly unrelated)
functions.
mascRNA folds similar to a tRNA cloverleaf secondary struc-
ture, allowing it to be recognized by several members of the
canonical tRNA processing machinery, such as RNase P, RNase
Z, and the CCA-adding enzyme. Unlike tRNAs, however,
mascRNA probably does not participate in transferring a specific
amino acid to a growing polypeptide chain during protein
synthesis because of its lack of a conserved anticodon loop
and failure to be aminoacylated. Other tRNA mimics have been
shown to be involved in viral replication (by being present at
the 30 end of the viral genomic RNA), translational regulation of
gene expression, group I intron splicing, and tagging of abnormal
proteins for proteolysis (reviewed in Giege´ et al., 1998; Fechter
et al., 2001). mascRNA does not likely participate in any of these
processes because MALAT1 is not translated or spliced, and
mascRNA fails to resemble bacterial tmRNAs that tag abnormal
proteins.
Although it is unclear what the exact function of the mascRNA
transcript is, its biogenesis is a direct consequence of transcrip-
tion of MALAT1. By being exported to the cytoplasm, mascRNA
may function as a transmittable signal to allow components of
the cytoplasm to sense that MALAT1 has been produced in
the nucleus without having to export MALAT1. Consistent with
this model, we determined that mascRNA has a relatively short928 Cell 135, 919–932, November 28, 2008 ª2008 Elsevier Inc.
Figure 7. MALAT1 Is Processed at Its 30 End to Yield mascRNA
Cleavage/polyadenylation can occur to yield a 7 kb mMALAT1 transcript, but this represents a minor product that is expressed at a very low level in cells.
MALAT1 is primarily processed via an upstream cleavage mechanism, which yields a mature 6.7 kb mMALAT1 transcript with a short poly(A) tail-like moiety
at its 30 end. Endonucleolytic cleavage by RNase P simultaneously generates the 30 end of the6.7 kbMALAT1 transcript and the 50 end of mascRNA. mascRNA
is then cleaved by RNase Z and subjected to CCA addition to generate the mature 61 nt mascRNA transcript, which is subsequently exported to the cytoplasm.half-life, thus allowing it to potentially serve a sensitive readout of
MALAT1 promoter activity. In addition, there is emerging evi-
dence that RNAs may function as signaling molecules, both
within and between cells (Dinger et al., 2008). Alternatively,
mascRNA may have a unique function limited to the cytoplasm.
For example, because of its similarity to tRNAs, mascRNA may
be involved in translational regulationby serving asa tRNAmimic.
The Abundant MALAT1 Transcript Has a Short Poly(A)
Tail-like Moiety
Practically all eukaryotic mRNAs, with the exception of histone
mRNAs, are thought to terminate in a poly(A) tail that is approx-
imately 200–250 residues in length in vertebrates (reviewed in
Proudfoot, 2004; Colgan and Manley, 1997; Zhao et al., 1999).
These poly(A) tracts are not encoded in the genome but are
added to nascent transcripts in a two-step reaction that involves
endonucleolytic cleavage followed by polyadenylation. It is,
therefore, not surprising that there are conserved polyadenyla-
tion signals at the 30 end of the MALAT1 locus that can be
used to generate a long MALAT1 isoform (7 kb in mouse).Unexpectedly, we found that this polyadenylated isoform is
present at a very low level in cells. Instead, the 30 end of MALAT1
is almost always generated several hundred nucleotides
upstream of the polyadenylation signals (to yield an 6.7 kb
isoform in mouse) via a mechanism that is in stark contrast to
classical cleavage/polyadenylation (Figure 7).
Within the nascent MALAT1 transcript, we identified a con-
served genomically encoded short poly(A)-rich tract. Our data
demonstrate that RNase P cleaves downstream of the poly(A)-
rich tract to yield a mature MALAT1 transcript with a poly(A)
tail-like moiety at its 30 end. In contrast to classical cleavage/
polyadenylation, no adenine residues are added subsequent to
cleavage. Because MALAT1 is nuclear retained and not trans-
lated, a long poly(A) tail may be unnecessary. Upon searching
the mouse and human genomes for sequences similar to the 30
end of MALAT1, we found one other instance. Perhaps not sur-
prisingly, it is at the 30 end of another long (>20 kb) noncoding
transcript that is retained in the nucleus (J.E.W. and D.L.S.,
unpublished data). All of the motifs we identified in MALAT1
(Figure S4) are present at the 30 end of the >20 kb transcript:Cell 135, 919–932, November 28, 2008 ª2008 Elsevier Inc. 929
the two upstream U-rich motifs, the poly(A)-rich tract, and a
predicted tRNA-like structure. Similar to MALAT1, the nascent
>20 kb transcript is cleaved immediately downstream of the
poly(A)-rich motif by RNase P, such that the mature transcript
has a short poly(A) tail-like moiety. These results suggest that
short poly(A) tail-like moieties may be a common feature at the
30 ends of at least some long nuclear-retained transcripts.
Short poly(A) tails (<20 nt) have previously been shown to
be present at the 30 ends of numerous mRNAs, especially in
developing oocytes (Richter, 1999; Gu et al., 1999; Choi and
Hagedorn, 2003). However, these short poly(A) tails are added
by a classical cleavage/polyadenylation mechanism. In some
cases, short poly(A) tails are just as effective as long poly(A) tails
at ensuring RNA stability (Peng et al., 2005). It is unclear whether
the poly(A)-rich tract at the 30 end of the mature MALAT1 tran-
script functions in the same manner as these previously identi-
fied short poly(A) tails. The abundant MALAT1 transcript does,
however, have a long half-life, suggesting that its poly(A) tail-
like moiety and nearby U-rich motifs are sufficient to ensure
RNA stability and resistance to exonucleases.
It is also unclear why the shorter MALAT1 isoform is expressed
at such a higher level than the longer polyadenylated isoform.
Regardless of whether the cleavage event occurs cotranscrip-
tionally or posttranscriptionally, processing must be efficient to
explain the drastic differences in steady-state levels between
MALAT1 isoforms. If cleavage occurs cotranscriptionally, it may
occur prior to the transcribing RNA polymerase reaching the
AAUAAA and other polyadenylation signals several hundred nu-
cleotides downstream. Rapid cleavage could be accomplished,
for example, by having the cleavage factor(s) be present in the
transcribing polymerase complex. On rare occasions when
upstream cleavage is delayed (e.g., because of improper RNA
folding), we propose that the downstream cleavage/polyadeny-
lation signals ensure transcriptional termination and thus
production of the longer polyadenylated MALAT1 transcript.
The present study has elucidated a mechanism by which
a long nuclear-retained noncoding RNA is processed at its 30
end to yield a short poly(A) tail-like moiety. RNase P cleavage
not only generates the 30 end of the abundant MALAT1 transcript
but also simultaneously generates the 50 end of a 61 nt tRNA-like
small RNA that is subsequently exported to the cytoplasm. Al-
though cleavage/polyadenylation is thought to take place at the
30 ends of almost all long eukaryotic RNA polymerase II tran-
scripts, the 30 end of the abundant MALAT1 transcript is not
defined in this manner. Instead, cleavage several hundred nucle-
otides upstream of the polyadenylation signals is the preferred
way by which the 30 end of MALAT1 is generated. Our findings
reveal a paradigm for how the 30 ends of certain RNA polymerase
II transcripts are produced. In addition, our results suggest a
general mechanism by which genetic loci are able to generate
multiple noncoding RNA transcripts, each of which localizes to
different subcellular compartments.
EXPERIMENTAL PROCEDURES
Cell Culture
EpH4-EV, EpH4-A6, and HeLa cells were grown at 37C, 5% CO2 in Dulbec-
co’s modified Eagle’s medium (DMEM) containing high glucose (Invitrogen,930 Cell 135, 919–932, November 28, 2008 ª2008 Elsevier Inc.Carlsbad, CA) supplemented with penicillin-streptomycin and 10% fetal
bovine serum (Hyclone Laboratories, Logan, UT). For inhibition of RNA
polymerase II transcription, HeLa cells were incubated with a-amanitin
(20 or 50 mg/ml; Sigma, St. Louis, MO) for 2 to 12 hr at 37C.
RNA Isolation
For isolation of small RNAs under 200 nt, the mirVana miRNA Isolation Kit was
used (Ambion, Austin, TX). Trizol was used for all total RNA isolations as per the
manufacturer’s instructions (Invitrogen). For isolation of poly(A)+ RNA, the
Oligotex mRNA Mini Kit was used (QIAGEN, Germantown, MD). Nuclear and
cytoplasmic fractionation andRNA isolationwere performed as described pre-
viously (Topisirovic et al., 2003). The FirstChoice Human Total RNA Survey
Panel (Ambion) was used to examine expression ofmascRNA in normal human
tissues.
Northern Blots
Small RNAs were separated by 15% denaturing polyacrylamide gel electro-
phoresis and electroblotted to Hybond N+ membrane (GE Healthcare,
Piscataway, New Jersey). For all northern blots using oligonucleotide probes,
ULTRAhyb-Oligo Hybridization Buffer was used as per the manufacturer’s
instructions (Ambion). Oligo probes were labeledwith [g-32P] ATPwith T4 poly-
nucleotide kinase (New England Biolabs, Ipswich, MA). For all northern blots
using random-labeled probes, NorthernMax Prehybridization/Hybridization
Buffer was used (Ambion). Labeling of random-labeled probes was performed
with the Prime-It RmT Random Primer Labeling Kit (Stratagene, La Jolla, CA).
Ambion Decade Markers were used as a ladder on small RNA northern blots.
Terminator 50-Phosphate-Dependent Exonuclease was used as per the
manufacturer’s instructions (Epicentre Biotechnologies, Madison, WI). Blots
were visualized and quantified with the Fujifilm Life Science FLA-5100 imaging
system. All oligonucleotide probe sequences and PCR primers are included in
the Supplemental Experimental Procedures.
For RNase H treatments, 10 mg of total RNA was first mixed with 20 pmol of
antisense oligo and heated to 65C for 10 min. After the antisense oligos were
allowed to anneal by slow cooling, the RNA was treated with RNase H (New
England Biolabs) at 37C for 30 min and then subjected to northern blot
analysis.
Ligation-Based Cloning
The 50 end of mascRNA was cloned with the GeneRacer kit (Invitrogen)
according to the manufacturer’s instructions, except that calf intestinal
phosphatase (CIP) and tobacco acid pyrophosphatase (TAP) treatments
were omitted. For cloning of the 30 ends of the mascRNA and MALAT1 tran-
scripts, the Modban oligo (IDT DNA Technologies, Coralville, IA) was ligated
to the 30 ends of total RNA similarly to a previously described procedure
(Lau et al., 2001).
Antisense Oligonucleotide Treatment
Uniform 20-O-methoxy ethyl substituted oligonucleotides with a full phopshor-
othioate backbone and 5-methyl U and C as the pyrimidine heterocycle were
prepared on solid support with standard phosphoramidite chemistry. All ASO
sequences are included in the Supplemental Experimental Procedures. ASOs
were administered at a final concentration of 100 nM to EpH4-EV cells with
Lipofectamine 2000 as per the manufacturer’s instructions (Invitrogen). Cells
were incubated with a mixture of Lipofectamine 2000 and oligonucleotide in
OptiMEM medium (Invitrogen) at 37C, 5% CO2. After 5 hr, the transfection
mixture was removed from the cells and replaced with fresh DMEM supple-
mented with 10% fetal bovine serum and incubated at 37C, 5% CO2 for
18–20 hr.
In Vitro Cleavage Assays
mMALAT1 RNA substrates were internally labeled with [a-32P] UTP, gel puri-
fied, and used at 10,000 cpm per cleavage reaction. Reactions with E. coli
M1 RNA were incubated at 37C for 1 hr in 50 mM Tris-HCl (pH 7.5), 100 mM
MgCl2, and 100 mM NH4Cl. Partially purified HeLa RNase P was generously
provided by Sidney Altman (Yale University). Reactions with human
RNase P were incubated at 37C for 1 hr in 50 mM Tris-HCl (pH 7.5), 10 mM
MgCl2, and 100 mM NH4Cl. Recombinant His-tagged tRNase ZL (delta30)
was generously provided by Masayuki Nashimoto (Niigata University), and
reactions were incubated at 37C for 30min in 10mMTris-HCl (pH 7.5), 1.5 mM
dithiothreitol (DTT), and 10 mM MgCl2. All reactions were stopped by the
addition of gel loadingdye, and sampleswere electrophoresed on8%polyacryl-
amide gels containing 8 M urea.
ACCESSION NUMBERS
Human and mouse mascRNA sequences have been deposited in GenBank
under accession numbers FJ209302 and FJ209303, respectively.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures and 13
figures and can be found with this article online at http://www.cell.com/
supplemental/S0092-8674(08)01301-9.
ACKNOWLEDGMENTS
Wewish to thank TomGingeras, Greg Hannon, Adrian Krainer, Kannanganattu
Prasanth, Hongjae Sunwoo, Oliver Tam, Jeff Wilusz, Carol Wilusz, Zhenyu
Xuan, and members of the Spector laboratory for many helpful discussions.
Wewould also like to thank Chris Black and Frank Bennett for help and discus-
sions regarding the antisense oligonucleotides, Josh Nichols andWalt Lima for
performing the sucrose gradients, Sidney Altman andMasayuki Nashimoto for
providing tRNA processing reagents, and Philip Leder for providing the EpH4-
EV and EpH4-A6 cell lines. We thank Delphine Bernard and Alain Bessis for
bringing MALAT1 to our attention. J.E.W. is supported by a Beckman Gradu-
ate Studentship at the Watson School of Biological Sciences. The work was
supported by a grant to D.L.S. from the National Institutes of Health, National
Institute of General Medical Sciences (42694).
Received: April 19, 2008
Revised: July 25, 2008
Accepted: October 7, 2008
Published: November 26, 2008
REFERENCES
Bass, B.L. (2002). RNA editing by adenosine deaminaes that act on RNA.
Annu. Rev. Biochem. 71, 817–846.
Birney, E., Stamatoyannopoulos, J.A., Dutta, A., Guigo, R., Gingeras, T.R.,
Margulies, E.H., Weng, Z., Snyder, M., Dermitzakis, E.T., Thurman, R.E.,
et al. (2007). Identifcation and analysis of functional elements in 1% of the
human genome by the ENCODE pilot project. Nature 447, 799–816.
Braidotti, G., Baubec, T., Pauler, F., Seidl, C., Smrzka, O., Stricker, S., Yotova,
I., and Barlow, D.P. (2004). The Air noncoding RNA: An imprinted cis-silencing
transcript. Cold Spring Harb. Symp. Quant. Biol. 69, 55–66.
Brennecke, J., Aravin, A.A., Stark, A., Dus, M., Kellis, M., Sachidanandam, R.,
and Hannon, G.J. (2007). Discrete small RNA-generating loci as master
regulators of transposon activity in Drosophila. Cell 128, 1089–1103.
Cai, X., and Cullen, B.R. (2007). The imprinted H19 noncoding RNA is a primary
microRNA precursor. RNA 13, 313–316.
Cai, X., Hagedorn, C.H., and Cullen, B.R. (2004). Human microRNAs are pro-
cessed from capped, polyadenylated transcripts that can also function as
a mRNAs. RNA 10, 1957–1966.
Carmell, M.A., Girard, A., van de Kant, H.J., Bourc’his, D., Bestor, T.H., de
Rooij, D.G., and Hannon, G.J. (2007). MIWI2 is essential for spermatogenesis
and repression of transposons in the mouse male germline. Dev. Cell 12,
503–514.
Carninci, P., Kasukawa, T., Katayama, S., Gough, J., Frith, M.C., Maeda, N.,
Oyama, R., Ravasi, T., Lenhard, B., Wells, C., et al. (2005). The transcriptional
landscape of the mammalian genome. Science 309, 1559–1563.Choi, Y.H., and Hagedorn, C.H. (2003). Purifying mRNAs with a high-affinity
eIF4E mutant identifies the short 30 poly(A) end phenotype. Proc. Natl. Acad.
Sci. USA 100, 7033–7038.
Colgan, D.F., and Manley, J.L. (1997). Mechanism and regulation of mRNA
polyadenylation. Genes Dev. 11, 2755–2766.
Conrad, N.K., Mili, S., Marshall, E.L., Shu, M.D., and Steitz, J.A. (2006).
Identification of a rapid mammalian deadenylation-dependent decay pathway
and its inhibition by a viral RNA element. Mol. Cell 24, 943–953.
Costa, F.F. (2005). Non-coding RNAs: New players in eukaryotic biology. Gene
357, 83–94.
Davis, I.J., His, B., Arroyo, J.D., Vargas, S.O., Yeh, Y.A., Motyckova, G., Valen-
cia, P., Perez-Atayde, A.R., Argani, P., Ladanyi, M., et al. (2003). Cloning of an
alpha-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome
translocation. Proc. Natl. Acad. Sci. USA 100, 6051–6056.
de la Sierra-Gallay, I.L., Pellegrini, O., and Condon, C. (2005). Structural basis
for substrate binding, cleavage and allostery in the tRNA maturase RNase Z.
Nature 433, 657–661.
Deng, X., and Meller, V.H. (2006). Non-coding RNA in fly dosage compensa-
tion. Trends Biochem. Sci. 31, 526–532.
Dinger, M.E., Mercer, T.R., and Mattick, J.S. (2008). RNA as extracellular
signaling molecules. J. Mol. Endocrinol. 40, 151–159.
Fantin, V.R., Berardi, M.J., Scorrano, L., Korsmeyer, S.J., and Leder, P. (2002).
A novel mitochondriotoxic small molecule that selectively inhibits tumor cell
growth. Cancer Res. 2, 29–42.
Fechter, P., Rudinger-Thirion, J., Florentz, C., and Giege´, R. (2001). Novel
features in the tRNA-like world of plant viral RNAs. Cell. Mol. Life Sci. 58,
1547–1561.
Filipowicz,W., Bhattacharyya, S.N., and Sonenberg, N. (2008). Mechanisms of
post-transcriptional regulation by microRNAs: Are the answers in sight? Nat.
Rev. Genet. 9, 102–114.
Ford, L.P., Watson, J., Keene, J.D., and Wilusz, J. (1999). ELAV proteins
stabilize deadenylated intermediates in a novel in vitro mRNA deadenylation/
degradation system. Genes Dev. 13, 188–201.
Giege´, R., Frugier, M., and Rudinger, J. (1998). tRNA mimics. Curr. Opin.
Struct. Biol. 8, 286–293.
Gopalan, V., Vioque, A., and Altman, S. (2002). RNase P: Variations and uses.
J. Biol. Chem. 277, 6759–6762.
Gu, H., Das Gupta, J., and Schoenberg, D.R. (1999). The poly(A)-limiting
element is a conserved cis-acting sequence that regulates the length of poly(A)
on nuclear pre-mRNAs. Proc. Natl. Acad. Sci. USA 96, 8943–8948.
Gunawardane, L.S., Saito, K., Nishida, K.M., Miyoshi, K., Kawamura, Y., Na-
gami, T., Siomi, H., and Siomi, M.C. (2007). A slicer-mediated mechanism
for repeat-associated siRNA 50 end formation in Drosophila. Science 315,
1587–1590.
Hopper, A.K., and Phizicky, E.M. (2003). tRNA transfers to the limelight. Genes
Dev. 17, 162–180.
Hutchinson, J.N., Ensminger, A.W., Clemson, C.M., Lynch, C.R., Lawrence,
J.D., and Chess, A. (2007). A screen for nuclear transcripts identifies two linked
noncoding RNAs associated with SC35 splicing domains. BMC Genomics 8,
39.
Jacobson, M.R., Cao, L.G., Taneja, K., Singer, R.H., Wang, Y.L., and
Pederson, T. (1997). Nuclear domains of the RNA subunit of RNase P. J. Cell
Sci. 110, 829–837.
Ji, P., Diedreichs, S., Wang, W., Boing, S., Metzger, R., Schneider, P.M.,
Tidow, N., Brandt, B., Buerger, H., Bulk, E., et al. (2003). MALAT-1, a novel
noncoding RNA, and thymosin beta4 predict metastasis and survival in
early-stage non-small cell lung cancer. Oncogene 22, 8031–8041.
Kapranov, P., Cheng, J., Dike, S., Nix, D.A., Duttagupta, R., Willingham, A.T.,
Stadler, P.F., Hertel, J., Hackermuller, J., Hofacker, I.L., et al. (2007). RNA
maps reveal new RNA classes and a possible function for pervasive transcrip-
tion. Science 316, 1484–1488.Cell 135, 919–932, November 28, 2008 ª2008 Elsevier Inc. 931
Kiss, T., Fayet, E., Jady, B.E., Richard, P., and Weber, M. (2006). Biogenesis
and intranuclear trafficking of human box C/D and H/ACA RNPs. Cold Spring
Harb. Symp. Quant. Biol. 71, 407–417.
Kuiper, R.P., Schepens, M., Thijssen, J., van Asseldonk, M., van den Berg, E.,
Bridge, J., Schuuring, E., Schoenmakers, E.F., and van Kessel, A.G. (2003).
Upregulation of the transcription factor TFEB in t(6;11)(p21;q13)-positive renal
cell carcinomas due to promoter substitution. Hum. Mol. Genet. 12,
1661–1669.
Lamond, A.I., and Spector, D.L. (2003). Nuclear speckles: A model for nuclear
organelles. Nat. Rev. Mol. Cell Biol. 4, 605–612.
Lau, N.C., Lim, L.P., Weinstein, E.G., and Bartel, D.P. (2001). An abundant
class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans.
Science 294, 858–862.
Lee, Y., Kim,M., Han, J., Yeom, K.H., Lee, S., Baek, S.H., and Kim, V.N. (2004).
MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 23,
4051–4060.
Lin, R., Maeda, S., Liu, C., Karin, M., and Edington, T.S. (2006). A large non-
coding RNA is a marker for murine hepatocellular carcinomas and a spectrum
of human carcinomas. Oncogene 26, 851–858.
Masui, O., and Heard, E. (2006). RNA and protein actors in X-chromosome in-
activation. Cold Spring Harb. Symp. Quant. Biol. 71, 419–428.
Mathews, D.H., Sabina, J., Zuker, M., and Turner, D.H. (1999). Expanded
sequence dependence of thermodynamic parameters improves prediction
of RNA secondary structure. J. Mol. Biol. 288, 911–940.
McKay, R.A., Miraglia, L.J., Cummins, L.L., Owens, S.R., Sasmor, H., and
Dean, N.M. (1999). Characterization of a potent and specific class of antisense
oligonucleotide inhibitor of protein kinase C-alpha expression. J. Biol. Chem.
274, 1715–1722.
Mercer, T.R., Dinger, M.E., Sunkin, S.M., Mehler, M.F., and Mattick, J.S.
(2008). Specific expression of long noncoding RNAs in the mouse brain.
Proc. Natl. Acad. Sci. USA 105, 716–721.
Monia, B.P., Lesnik, E.A., Gonzalez, C., Lima, W.F., McGee, D., Guinosso,
C.J., Kawasaki, A.M., Cook, P.D., and Freier, S.M. (1993). Evaluation of
20-modified oligonucleotides containing 20-deoxy gaps as antisense inhibitors
of gene expression. J. Biol. Chem. 268, 14514–14522.932 Cell 135, 919–932, November 28, 2008 ª2008 Elsevier Inc.Peng, J., Murray, E.L., and Schoenberg, D.R. (2005). The poly(A)-limiting
element enhances mRNA accumulation by increasing the efficiency of pre-
mRNA 30 processing. RNA 11, 958–965.
Prasanth, K.V., and Spector, D.L. (2007). Eukaryotic regulatory RNAs: An
answer to the ‘‘genome’’ complexity conundrum. Genes Dev. 21, 11–42.
Proudfoot, N. (2004). New perspectives on connecting messenger RNA 30 end
formation to transcription. Curr. Opin. Cell Biol. 16, 272–278.
Rajaram, V., Knezevich, S., Bove, K.E., Perry, A., and Pfeifer, J.D. (2007). DNA
sequence of the translocation breakpoints in undifferentiated embryonal sar-
coma arising in mesenchymal hamartoma of the liver harboring the
t(11;19)(q11;q13.4) translocation. Genes Chromosomes Cancer 46, 508–513.
Richter, J.D. (1999). Cytoplasmic polyadenylation in development and beyond.
Microbiol. Mol. Biol. Rev. 63, 446–456.
Szymanski, M., Barciszewska, M.Z., Erdmann, V.A., and Barciszewski, J.
(2005). A new frontier for molecular medicine: Noncoding RNAs. Biochim.
Biophys. Acta 1756, 65–75.
Topisirovic, I., Culjkovic, B., Cohen, N., Perez, J.M., Skrabanek, L., and
Borden, K.L. (2003). The proline-rich homeodomain protein, PRH, is a
tissue-specific inhibitor of eIF4E-dependent cyclin D1 mRNA transport and
growth. EMBO J. 22, 689–703.
Varshney, U., Lee, C., and RajBhandary, U.L. (1991). Direct analysis of amino-
acylation levels of tRNAs in vivo. J. Biol. Chem. 266, 24712–24718.
Vasudevan, S., Tong, Y., and Steitz, J.A. (2007). Switching from repression to
activation: MicroRNAs can up-regulate translation. Science 318, 1931–1934.
Vogel, A., Schilling, O., Spath, B., and Marchfelder, A. (2005). The tRNase Z
family of proteins: Physiological functions, substrate specificity and structural
properties. Biol. Chem. 386, 1253–1264.
Weiner, A.M., and Maizels, N. (1987). tRNA-like structures tag the 30 ends of
genomic RNA molecules for replication: Implications for the origin of protein
synthesis. Proc. Natl. Acad. Sci. USA 84, 7383–7387.
Zhao, J., Hyman, L., and Moore, C. (1999). Formation of mRNA 30 ends in
eukaryotes: Mechanism, regulation, and interrelationships with other steps
in mRNA synthesis. Microbiol. Mol. Biol. Rev. 63, 405–445.
Zuker, M. (2003). Mfold web server for nucleic acid folding and hybridization
prediction. Nucleic Acids Res. 31, 3406–3415.
